Lius laboratory has presented advancement technologies to the field of genome editing, consisting of base modifying and prime modifying, with the goal of treating genetic illness. In their most current work, his research team took a “no stone unturned” approach to figure out a one-time base editing strategy to deal with the motor nerve cell illness, back muscular atrophy (SMA). David Liu, PhDRichard Merkin ProfessorDirector, Merkin Institute of Transformative Technologies in HealthcareDirector, Chemical Biology and Therapeutic Sciences ProgramThomas Dudley Cabot Professor, Natural SciencesProfessor, Chemistry and Chemical BiologyHarvard UniversityCore Institute Member and Faculty Vice-Chair, Broad InstituteInvestigator, Howard Hughes Medical Institute
